Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Galmed Pharmaceuticals Ltd. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +3 vs. Q2 2022
- Shares held
- 2.59M
- +63.1K (+2.5%) vs. Q2 2022
- Total value
- $803.6K
- −$895.8K (−52.7%) vs. Q2 2022
- New holders
- 5
- 3 more added
- Sold out
- 2
- 7 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EOCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $85.9K |
| Q1 2026 | 16 | $71.2K |
| Q4 2025 | 17 | $166.4K |
| Q3 2025 | 14 | $102.0K |
| Q2 2025 | 15 | $140.2K |
| Q1 2025 | 13 | $80.4K |
| Q4 2024 | 12 | $142.8K |
| Q3 2024 | 10 | $38.3K |
| Q2 2024 | 13 | $112.9K |
| Q1 2024 | 13 | $57.6K |
| Q4 2023 | 14 | $248.8K |
| Q3 2023 | 17 | $428.2K |
| Q2 2023 | 12 | $419.1K |
| Q1 2023 | 21 | $878.3K |
| Q4 2022 | 22 | $1.21M |
| Q3 2022 | 25 | $803.6K |
| Q2 2022 | 22 | $1.70M |
| Q1 2022 | 23 | $4.47M |
| Q4 2021 | 24 | $7.05M |
| Q3 2021 | 26 | $11.8M |
| Q2 2021 | 25 | $14.6M |
| Q1 2021 | 30 | $19.4M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Galmed Pharmaceuticals Ltd.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 1,799,694 | $558.0K | 0.02% | 00.0% | Unchanged |
| Morgan Stanley | 189,620 | $59.0K | 0.00% | −6,079−3.1% | Reduced |
| Raymond James & Associates | 155,940 | $49.0K | 0.00% | −1,500−1.0% | Reduced |
| Western Wealth Management, LLC | 59,074 | $19.0K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Services Advisors, Inc. | 58,310 | $18.0K | 0.00% | −6,000−9.3% | Reduced |
| Renaissance Technologies LLC | 50,789 | $16.0K | 0.00% | +19,189+60.7% | Added |
| Millennium Management LLC | 46,866 | $15.0K | 0.00% | −3,882−7.6% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 35,115 | $11.0K | 0.00% | +8,000+29.5% | Added |
| Geode Capital Management, LLC | 27,177 | $8.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 26,986 | $8.00K | 0.00% | +20,922+345.0% | Added |
| Virtu Financial LLC | 22,548 | $7.00K | 0.00% | +22,548 | New |
| Citadel Advisors LLC | 18,628 | $6.00K | 0.00% | −40,997−68.8% | Reduced |
| Two Sigma Securities, LLC | 18,512 | $6.00K | 0.00% | +18,512 | New |
| BNP Paribas Arbitrage, SA | 14,290 | $4.45K | 0.00% | +14,290 | New |
| Brave Asset Management Inc | 11,470 | $4.00K | 0.00% | 00.0% | Unchanged |
| Ground Swell Capital, LLC | 13,028 | $4.00K | 0.01% | +13,028 | New |
| Jane Street Group, LLC | 13,904 | $4.00K | 0.00% | +13,904 | New |
| Susquehanna International Group, LLP | 10,001 | $3.00K | 0.00% | −102−1.0% | Reduced |
| Wells Fargo & Company | 4,050 | $1.00K | 0.00% | −2,280−36.0% | Reduced |
| TSFG, LLC | 3,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1,785 | $1.00K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 2,500 | $778 | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 1,000 | $423 | 0.00% | 00.0% | Unchanged |
| PYA Waltman Capital, LLC | 1,000 | $0 | 0.00% | 00.0% | Unchanged |
| Bourgeon Capital Management LLC | 500 | $0 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 0 | $0 | 0.00% | −3,700−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,750−100.0% | Sold out |